FDA Pilot Program Eases Rules for Nicotine Pouch Makers

The U.S. Food and Drug Administration (FDA) is softening its stance on nicotine pouches through a new pilot program, signaling a shift in tobacco regulation under the Trump administration. Traditionally, the FDA required extensive product-specific studies before authorizing new nicotine products, aiming to ensure they improved public health without sparking youth use.

According to internal meeting transcripts reviewed by Reuters, the FDA will now ease these requirements. Manufacturers will no longer need to submit certain studies, such as those proving a product’s effectiveness in helping smokers cut back. Instead, the agency will rely on existing research on nicotine pouches.

This change could speed up reviews for major tobacco companies like Philip Morris International, Altria, and British American Tobacco, whose pouch brands Zyn, On! and Velo dominate the U.S. market. While PMI and Altria withheld comment, BAT welcomed a more streamlined process, calling sensible regulation vital for public health.

FDA officials, however, stressed that scientific standards remain in place. Bret Keplow, acting director of the Center for Tobacco Products, noted the pilot could influence future reviews of other nicotine products, including vapes. Internal discussions also highlighted that nicotine pouches carry fewer toxic risks than cigarettes and have not triggered significant youth adoption so far.

Experts remain divided. Supporters argue that quicker approvals could expand access to less harmful cigarette alternatives. Critics, including former FDA tobacco directors, caution that product-specific studies remain essential to confirm safety, public health benefits, and to prevent youth misuse. Analysts predict the pilot will accelerate pouch sales, though clinical studies will still be required in some areas.

The move represents the FDA’s first clear step toward a more flexible regulatory framework for smoking alternatives in the world’s largest nicotine market.